The Conversation (0)
Theralase Technologies announced research on the company’s licensed Osmium PDCs was independently reviewed.
Theralase Technologies (TSXV:TLT; OTCQX:TLTFF) announced research on the company’s licensed Osmium PDCs was independently reviewed.
As quoted in the press release:
Edith C. Glazer, Ph.D., Associate Professor, Department of Biological Chemistry, University of Kentucky, Lexington, Kentucky provided an independent review of “Novel Osmium-based Coordination Complexes as Photosensitizers for Panchromatic Photodynamic Therapy,” where she states, “The validation of Osmium coordination complexes as photosensitizers for PDT, with very promising in vivo results, demonstrate radical improvements in survival following irradiation with visible (635 nm) or Near InfraRed (“NI“) (808 nm) light.
The original article describes how, “Cancer remains a major global malaise requiring the advent of new, efficient and low-cost treatments. PDT, which combines a photosensitizer and photons to produce cytotoxic reactive oxygen species, has been established as an effective cancer treatment but has yet to become mainstream. One of the main limitations has been the paucity of photosensitizers that are effective over a wide range of wavelengths, can exert their cytotoxic effects in hypoxia (low oxygen), are easily synthesized and produce few if any side effects.
Click here to read the full press release.
Source: www.accesswire.com